Semax: a nootropic research peptide

Semax is a synthetic peptide originally derived from a fragment of adrenocorticotropic hormone (ACTH) and studied extensively in the research literature for its effects on cognition and the nervous system. It is a frequent subject of nootropic and neuroprotective research.

A peptide from an ACTH fragment

Semax is a short synthetic sequence based on a naturally occurring ACTH fragment, modified to improve stability in laboratory conditions. Unlike the parent hormone, it is studied without the hormonal activity of full-length ACTH, which makes it a focused tool for investigating central-nervous-system pathways.

What researchers investigate

In preclinical models, Semax is examined for its role in learning, memory, and attention-related pathways, as well as neuroprotection under stress. Much research focuses on its association with brain-derived neurotrophic factor (BDNF) and related signalling. As with all research peptides, these findings describe activity in controlled models and are not statements about human outcomes.

Relationship to Selank

Semax and Selank are often studied side by side, since both are short synthetic peptides applied in neurological research models, one framed around nootropic pathways and the other around anxiolytic ones. Comparing them lets researchers explore how small sequence differences shape activity.

Handling and quality

Semax ships as a lyophilised powder reconstituted with bacteriostatic water, and every Vela order includes a free 3 mL bacteriostatic water vial. Every batch ships with a certificate of analysis so identity and purity are confirmed before research begins.